Episodebeskrivelse
Australia’s Health Technology Assessment (HTA) system is undergoing its first major reform in more than three decades. With new medicines, vaccines, and devices evolving faster than ever, how can we modernise our approval processes to keep pace - while still ensuring safety, value, and equitable access?
Elizabeth de Somer, CEO of Medicines Australia, explains what the HTA Review is really about, why it matters for patients and the healthcare system, and how Australia can better engage consumers in the evaluation of new technologies.
📥 JOIN Amplieo+ on Substack for early access to episodes…
Nettsted: amplieo.substack.com

